Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

ARORA, SEEMA

NPI: 1598712523 · WALPOLE, MA 02081 · Internal Medicine Physician · NPI assigned 05/27/2006

$553K
Total Medicaid Paid
7,125
Total Claims
5,548
Beneficiaries
5
Codes Billed
2018-01
First Month
2024-09
Last Month

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 729 $42K
2019 1,631 $96K
2020 1,375 $112K
2021 1,314 $119K
2022 1,117 $100K
2023 581 $52K
2024 378 $33K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 2,067 1,675 $256K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 2,966 2,350 $173K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1,060 765 $50K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 575 414 $47K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 457 344 $27K